Evidence map›Paper›PMID 42871298›Full record

ArticleFrontiers in neuroscience2026

Towards a nonlinear "neuroimmune gate-model": beyond stellate ganglion block and vagus nerve stimulation.

Lorenz Fischer, Hans-Georg Schaible

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lorenz FischerNeural Therapy, University of Bern, Bern, Switzerland.
Hans-Georg SchaibleInstitute of Physiology/Neurophysiology, Jena University Hospital, Friedrich-Schiller-University Jena, Jena, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We propose a three-level neuroimmune gate model to characterize the communication between the nervous system and the immune system. The first gate, Gate 1, is the peripheral neuroimmune gate. Here, immune cells, inflammatory mediators, sensory neurons, autonomic nervous system neurons, blood vessels, and specific tissue components interact. The second gate, Gate 2, is the spinal neuroimmune gate and includes spinal afferents, spinal neurons and circuits, preganglionic sympathetic neurons, and microglia. The third gate, Gate 3, comprises supraspinal structures, including the nucleus tractus solitarii (NTS), the rostral ventrolateral medulla (RVLM), the locus coeruleus, the hypothalamus, and corticolimbic circuits. These three gates are functional centers that process and integrate inflammatory and neuronal signals dynamically and nonlinearly. This process can amplify or attenuate inflammatory reactions and disease states. The gates communicate with each other via neuronal pathways and humoral mediators. Sympathetic pro-inflammatory influences, vagal anti-inflammatory influences, and preexisting pro-inflammatory conditions (preload) are particularly important in all three gates. Unfavorable nonlinear interactions within and between these gates may cause tissue-threatening stimuli to evoke exaggerated responses, such as hyperinflammation. Understanding the three gates and their interactions can provide a conceptual framework for diagnosis and intervention. With this in mind, we will discuss the benefits of nonlinear therapeutic approaches, such as stellate ganglion blockade (SGB) and vagus nerve stimulation (VNS). We propose considering SGB and VNS as nonlinear therapeutic approaches with the capacity to close the proinflammatory neuroimmune gates based on endogenous regulatory mechanisms.

Indexed as

neuroimmune gate modelneurosciencenonlinearitystellate ganglion blockvagus nerve stimulation

Identifiers

PMID42871298
PMCPMC13658464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.